Drug intelligence / Profile preview

WSK-V304

Development stage: Preclinical
Lead developer: WestVac Biopharma
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Parenteral

Overview

WSK-V304 is a recombinant protein vaccine being developed by WestVac BioPharma for the treatment of pulmonary fibrosis. The vaccine is designed to induce an immune response against specific fibrosis-related antigens, aiming to mitigate or reverse the progression of fibrotic tissue in the lungs. As of mid-2024, the program is in the IND-enabling stage, with applications for Investigator-Initiated Trials (IIT) in progress.

Other names: WSK-V304WSK-V-304WSK-V 304

Beyond the preview

Go deeper on WSK-V304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSK-V304.

Explore the full profile